FDA Approves Tagrisso (osimertinib) for Stage 3 (III) NSCLC Following Chemoradiation
On September 25, 2024, the U.S. Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for people with unresectable stage 3 (III) non-small cell lung cancer (NSCLC). It’s approved for people who have both: Disease that has not progressed during [...]